1,721,676 research outputs found
Epithelial ICAM-1 regulation and its role in allergy
No full textEpithelial ICAM-1 regulation and its role in allerg
Treatment strategies in mild asthma
No full textPURPOSE OF THE REVIEW: More than 10 years ago the category of mild asthma was split into mild intermittent and mild persistent asthma and maintenance therapy with low dose inhaled corticosteroids (ICS) was recommended for mild persistent asthma. The threshold for instituting regular ICS therapy was arbitrarily chosen, in the absence of clinical studies specifically addressing this issue. RECENT FINDINGS: The results of recent trials have questioned the assumption that all patients at the mild end of the asthma severity spectrum should be committed to regular anti-inflammatory treatment with inhaled corticosteroids. As a consequence, the identification of the relevant outcomes for the treatment of mild persistent asthma has become a matter of discussion, which has provided the rationale to test the efficacy and well tolerance of new strategies, other than guidelines-recommended regular low-dose ICS, for the treatment of mild persistent asthma. SUMMARY: Several approaches have been evaluated with some promising results, to include the combination of ICS and long-acting b2-agonists, oral leukotriene antagonists, and the intermittent or as-needed use of ICS in the absence of regular treatment. Conversely, little effort has been made to evaluate therapeutic options other than as-needed bronchodilation in mild intermittent asthma
A new combination therapy for asthma: bridging the gap between effectiveness in trials and clinical practice?
No full texthe goal of asthma management is to achieve and maintain control of symptoms. Although inhaled corticosteroids (ICSs) represent the cornerstone of asthma therapy, the combination of a long-acting β2-agonist (LABA) with an ICS is the treatment option advocated in patients whose asthma is not controlled with low-dose ICS monotherapy. It is well recognized that ICS/LABA therapy can significantly improve asthma symptoms and control compared with simply increasing a patient's ICS dosage. Therapy with an ICS/LABA combination via a single inhaler may offer significant benefits over the use of separate inhalers, facilitating patient adherence to both the ICS and LABA components of the treatment regimen. Furthermore, when ICSs and LABAs are administered as a single-aerosol combination, they may interact synergistically at the molecular level within the lung, enhancing their overall pharmacological, and potentially therapeutic, effect
Inhaled BDP/Formoterol extra-fine combination. Evidence and future perspectives
No full textThe combination of inhaled corticosteroids (ICS) and long acting Beta-2 agonists (LABA) represents the mainstay of current treatment of moderate to severe persistent asthma. Corticosteroids and LABA combine the main pillars of asthma therapy--inhibition of inflammation and bronchodilation--and they may potentiate each other when they simultaneously reach the pharmacological target. A new extra-fine formulation containing the combination of inhaled beclometasone (BDP) and formoterol (F) (with the non polluting HFA-Hydrofluoroalkane-134a as propellant) is now available on the market. The extra-fine formulation increases the deposition into the peripheral airways and a greater proportion of the inhaled compound reaches the pharmacological target. Thus, the dose of ICS can be decreased and the risk-benefit profile improves. The efficacy and tolerance of BDP/F extra-fine combination has been documented in randomized clinical trials into which patients with moderate to severe asthma were included. These trials confirmed that the new extra-fine combination is as effective as the other fixed combinations. Georg Thieme Verlag KG Stuttgart.New York
Investigating the steroids and long-acting beta(2)-agonists combination: why do we need more?
No full textInvestigating the steroids and long-acting beta 2-agonists combination: why do we need mor
Pathogenic link between chronic obstructive pulmonary disease and squamous cell lung cancer
No full text--
Telithromycin in acute exacerbations of asthma
No full textTelithromycin in acute exacerbations of asthm
Severe asthma: Pragmatic clinical lumping and time for investigational splitting
No full textImproved care of severe asthma is a major unmet medical need. Indeed, although most asthma can be relatively well controlled by the use of currently available medications, 5–10% of asthma remains refractory to current gold standards for its treatment. The European Respiratory Society/American Thoracic Society Task Force on severe asthma was charged “to revise the definition of severe asthma, discuss the possible phenotypes and provide guidance about the management of patients with severe asthma” with a target audience of specialists. It was further charged to develop a document that might serve “as the basis for development and implementation of locally-adopted guidelines.” The authors are to be congratulated for a comprehensive and scholarly work. They do indeed update the definition of severe asthma, they provide a scholarly review of research in the area, they emphasize how evolving phenotypes will eventually improve our treatment of the disease, and they make recommendations regarding treatment
Smoking history effect on peripheral lung inflammation and gene transcription in chronic obstructive pulmonary disease
No full text--
- …
